NCT03601351View on ClinicalTrials.gov

MOR-1 Expression in Colorectal Cancer and Disease-free Survival Relationship. Five-year Follow-up.

CompletedOBSERVATIONAL
Enrollment

174

Participants

Timeline

Start Date

May 4, 2018

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Colorectal Cancer
Interventions
OTHER

ELISA for MOR-1 expression

To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.

Trial Locations (1)

Unknown

Hospital Universitario La Fe, Valencia

All Listed Sponsors
lead

Hospital Universitario La Fe

OTHER

NCT03601351 - MOR-1 Expression in Colorectal Cancer and Disease-free Survival Relationship. Five-year Follow-up. | Biotech Hunter | Biotech Hunter